Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Stereotactic Body Radiotherapy
•
Prostate Cancer
What fractionation and dose constraints do you use for prostate SBRT?
Answer from: Radiation Oncologist at Community Practice
UCLA King Protocol8 Gy x5PTV 95% of PTV volume to get 95-110% rx doseRectum V50 (20 Gy) < 50%V80 (32 Gy) < 20%V90 (36 Gy) < 10 %V100 (40Gy) < 5%BladderV50 (20 Gy) < 40%V100 (40 Gy) < 1.1%Femurs V40 (16 Gy) < 5%Small Bowel V50 (20Gy) < 1%
Sign in or Register to read more
380
Related Questions
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Given the PATRIOT trial and hypo-FLAME 2.0, do you consider once-a-week prostate SBRT instead of every other day?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?